MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Liabilities
Everything the company owes to creditors and other parties.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 2.1% from a year ago
Total liabilities stood at $18.95M at the end of Q1 FY2026, up 2.1% from a year earlier and down 10.3% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Total liabilities amounted to 4.5% of total assets at the end of Q1 FY2026, down 12.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +2.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 21.14M USD
- Year-over-year change
- -2.7%
- 3-year CAGR
- +4.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.14M | -2.7% |
| FY2024 | 2024-12-31 | 21.72M | +7.9% |
| FY2023 | 2023-12-31 | 20.13M | +8.7% |
| FY2022 | 2022-12-31 | 18.52M | — |
Total Liabilities vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total liabilities of $18.95M is the 8th highest of the 11 companies compared; the peer median is $30.12M.
- Its year-over-year change of +2.1% is the 7th highest of 11, against a peer median of +19.2%.
- Total liabilities amounts to 4.5% of total assets for MPLT, versus a peer median of 10.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $296.65B | +474318.1% | +47.0% | 312.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $106.25M | -0.1% | +78.1% | 9.9% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M | +193.1% | -53.6% | 54.1% |
| Mar 2026 | $72.78M | -44.7% | +47.9% | 26.1% | |
| Mar 2026 | $32.89M | +0.2% | -27.8% | 11.9% | |
| Mar 2026 | $27.36M | +22.3% | -4.1% | 12.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Mar 2026 | $18.95M | +2.1% | +4.5% | 4.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $14.79M | +66.9% | -38.6% | 3.8% |
| Mar 2026 | $11.89M | +16.1% | +23.3% | 4.3% | |
| Dec 2025 | $6.37M | -51.5% | -4.3% | 4.8% | |
| Peer median (excluding MPLT) | $30.12M | +19.2% | +9.6% | 10.9% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.